The conversation discusses hair loss progress pictures, highlighting noticeable improvement. Treatments mentioned include finasteride (Fin) and dutasteride (Dut).
A 24-year-old with thinning hair and receding sides is considering using Minoxidil and finasteride to improve hair thickness. They are seeking general expectations for these treatments, acknowledging individual results may vary.
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
The conversation is about a user trying topical melatonin mixed with minoxidil to reduce hair shedding after not seeing desired results with finasteride and minoxidil alone. Another user suggests that instead of daily updates, the original poster should share their results after a few weeks.
The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.
The conversation discusses the best vehicle for topical dutasteride, comparing Trichosol, Transcutol, and a gel version. It also mentions using Transcutol with ethanol to enhance transdermal delivery of Bimatoprost.
The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.
The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.
Girl finds guy's hair building fibers, sparking discussion on hair's role in attraction and self-esteem. Treatments like Minoxidil, finasteride, and hair systems are mentioned.
Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.
Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.
The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.
The user is considering another hair transplant or scalp micropigmentation (SMP) for a congenital bald spot, but previous transplants were less effective due to scar tissue. Suggestions include using hair fibers, changing hairstyles, or doing nothing, as the spot is not very noticeable.
A topical treatment called 1961, containing multiple products, is discussed for its compatibility with finasteride. It is suggested that 1961 does not negatively affect finasteride's effectiveness and may even enhance its absorption.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
A user is comparing Capillus Ultra and Capillus ONE for hair loss treatment, questioning if the number of diodes matters. Another user suggests the OMG helmet as the only worthwhile option.
Celebrities often maintain perfect hairlines through expensive transplants and common drugs like finasteride and dutasteride. Despite potential side effects, the importance of their appearance makes these treatments worthwhile.
A user has been using a topical hair loss treatment with finasteride, minoxidil, and tretinoin for 4 years without satisfactory results and is considering switching to a different product due to concerns about effectiveness and company reliability. They are seeking others' experiences with Strut and alternative products before making a change.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.